July 2 2002
02 July 2002
Veenendaal, The Netherlands (July 1st, 2002) - Nucletron BV today announced an agreement with BSD Medical Corporation (USA) (OTCBB:BSDM) in which Nucletron has become exclusive worldwide sales agent for BSD Medical Corporation's new generation of systems for interstitial hyperthermia therapy. "Interstitial hyperthermia is an interesting complimentary treatment modality to brachytherapy. A combination with interstitial hyperthermia could increase the tumor sensitivity and contribute to significantly better clinical results" said Rudolf L. Scholte President & CEO of Nucletron B.V.. Hyrum A. Mead, President of BSD Medical Corporation said, “Nucletron and BSD Medical have much in common because the combined use of brachytherapy (by Nucletron) and microwave hyperthermia (by BSD Medical) in the treatment of cancer can substantially improve results in cancer treatment. It is a winning combination for both our patients and our respective companies.” Interstitial Hyperthermia complements brachytherapy, employing the same catheters used to perform the HDR treatment as a passage for tiny microwave antennae. These antennae provide hyperthermia therapy. Hyperthermia sensitizes the tumor to radiation treatment and can improve significantly the outcome for the patient. Therefore the combination of the two techniques in one treatment step will be a significant step forward. About BSD Medical Corporation: is the foremost developer of hyperthermia systems, and has all of the FDA market approvals that have been issued for cancer therapy using microwave interstitial hyperthermia. BSD Medical also has an exclusive license with the University of California San Francisco (UCSF) that provides a novel variable microwave heating pattern applicable to microwave interstitial hyperthermia. For further information about BSD Medical, visit the BSD web site at ( http://www.bsdmc.com/ ) About Nucletron B.V.: Nucletron B.V., with headquarters in Veenendaal, The Netherlands, is a worldwide leader in radiotherapy systems, and specializes in some of the most innovative products used for cancer treatment. The company has 11 offices worldwide, including its corporate headquarters in the Netherlands. Nucletron is the world leader in remote afterloading brachytherapy, supplying the majority of all systems worldwide. Nucletron B.V. , is a subsidiary of Delft Instruments, http://www.delftinstruments.com/, an international group of companies with some 1000 employees and annual sales of almost Euro 200 million. Contact: Mark Adam - GMEMEA Nucletron BV, The Netherlands fml@nucletron.com
Or
Nina Yerge -Corporate Communications Nucletron Corporation USA phone, 410-312-4127 fax, 410-312-4126 yerge@nucusa.com